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Approaches in Molecular Bioengineering
Michael A. Nash*ab
Abstract: Protein sequences inhabit a discrete set in macromolecular space with incredible capacity to treat
human disease. Despite our ability to program and manipulate protein sequences, the vast majority of protein
development efforts are still done heuristically without a unified set of guiding principles. This article highlights
work in understanding biophysical stability and function of proteins, developing new biophysical measurement
tools and building high-throughput screening platforms to explore functional protein sequences. We highlight two
primary areas. First, molecular biomechanics is a subfield concerned with the response of proteins to mechanical
forces, and how we can leverage mechanical force to control protein function. The second subfield investigates
the use of polymers and hydrogels in protein engineering and directed evolution in pursuit of new molecular
systems with therapeutic applications. These two subdisciplines complement each other by shedding light onto
sequence and structural features that can be used to impart stability into therapeutic proteins.
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Introduction
Protein Sequence Space
Consider for a moment that the number of protein sequences
63 amino acids in length is greater than the number of atoms in the
known universe (1080). Next consider that an average human protein
has a length of approximately 450 amino acids. These simple cal-
culations indicate that protein sequence space, although discrete, is
unbelievably vast.And yet our ability to addressmedical challenges
in the coming decades will depend on our capacity to efficiently
search and characterize sequence and function within this space.
My research group at the University of Basel and ETH Zurich
is motivated by this challenge to understand the functional space
of protein sequences in pursuit of new therapies. I hope that by
preparing this article for a general chemically literate audience
as part of the 2020 ‘News from New Professors in Switzerland’
Chimia special issue, I am able to introduce the chemical commu-
nity in Switzerland and abroad to thematic areas we are actively
pursuing in my lab, and provide a useful primer to those looking
into these topics for the first time. By studying single-molecule un-
folding and unbinding reactions using force microscopy, and uti-
lize single-cell approaches to evolve new functions in therapeutic
enzymes, wework at the information limit of living systems. I have
split the content into two sections focusing on (1) molecular bio-
mechanics, and (2) polymers and hydrogels in protein engineering.
Protein Biopharmaceuticals
The main application area of our single-cell and single-mol-
ecule engineering approaches is in biopharmaceuticals. Over the
last 20 years, biological therapeutics have emerged as the fastest
growing sector of the pharma industry, comprising over half of
first-time approvals from 2015–2018,[1] and representing close
to 40% of approvals in 2019.[2] Biological therapeutics fall into
several categories, the most prominent classes of which are mono-
clonal antibodies, in addition to other classes including antibody
drug conjugates, therapeutic enzymes, peptides, vaccines in sev-
eral formats, and small interfering RNA.
Whereas small molecule therapeutics consist of a few dozen
atoms arranged in an atomically defined configuration lacking
higher order structure, biologics consist of thousands of atoms that
fold into complex 3D shapes that adopt a configuration belonging
to a family of protein folds. Macromolecular therapeutics can be
more specific in the body than small molecules, and can be artifi-
cially evolved in laboratory with genetic engineering, but enhanced
specificity and evolvability come at a cost of ensuring stable fold-
ing duringmanufacturing, storage, and administration. Particularly
the issues of protein folding, secondary and tertiary structural sta-
bility and post-translational modifications come into play. The
three-dimensional structure of protein therapeutics is in fact not
atomically defined but exists as an ensemble of conformations that
are sampled by the molecule on the nanosecond timescale (Fig. 1).
Part 1 – Molecular Biomechanics
Biophysical Stability at Equilibrium
Developability refers to a range of properties including a
biologic’s feasibility of manufacture and storage, folding stabil-
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equilibrium. Furthermore, the manufacture of protein biopharma-
ceuticals in bioreactors occurs in environments that are far from
equilibrium. For these reasons, we believe that studying non-equi-
librium stability of biotherapeutics can provide unique insights
into protein-based biopharmaceuticals.
Single-molecule Mechanical Manipulation with the
Atomic Force Microscope (AFM)
Fluid cells for the atomic force microscope were introduced in
1989,[4] and the era of bio-AFM rapidly developed with the advent
of single-molecule protein imaging under native conditions.[5,6]
Researchers discovered they could probe non-covalent protein
and DNA interactions under force using functionalized AFM
tips.[7–12] Repetitive natural polyproteins such as smooth muscle
Titin[13,14] or polyubiquitin chains[15,16] with multi-domain struc-
tures were found to provide regularly spaced repeating saw-tooth-
like force-extension curves when stretched under tension. Each
peak of the saw tooth corresponds to unfolding of a single domain
within the polyprotein. This approach was utilized for generat-
ing artificial recombinant polyproteins comprising typically im-
munoglobulin domains that provided internal molecular controls
for understanding mechanical unfolding of embedded domains of
interest. Since these early developments, single-molecule AFM
using polyproteins[17–23] has provided detailed information about
the relationships between secondary/tertiary structure and me-
chanical stability.
My lab has developed several methodological innova-
tions[24–27] for improving the throughput and data quality[18,28] in
single-molecule stretching experiments in order to gain insight
into mechanostable receptor ligand interactions derived from
adhesive bacteria.[29–31] We have implemented molecular finger-
printing approaches for ensuring the validity of single-molecule
receptor-ligand interactions (Fig. 2) whereby two domains with
well-known unfolding patterns are fused with the receptor and
ligand, respectively. Upon formation of the receptor–ligand com-
plex and retraction of the cantilever, unfolding of the two finger-
print domains in series indicates successful loading of a single-
complex. We have also implemented site-specific protein ligation
chemistry based on a variety of enzymes,[24,26] including Sfp,
Sortase, or using isopeptide bond formation (Spytag/Spycatcher).
These methods have allowed us to increase the statistical power of
our analyses in characterizing mechanostable bacterial adhesion
proteins,[27,30–33] and therapeutic nanobodies.[34]
Protein mechanical stability is an important non-equilibrium
stability parameter that can influence behavior in vivo.Mechanical
stability describes how much tension a fold can bear before it
unfolds, or how much force a receptor–ligand complex can with-
stand before breaking. Since force is a vector and not a scalar
quantity, the mechanical response of a given protein strongly de-
pends on the direction over which force is applied. Mechanically
denaturing a protein by stretching it between its N- and C-termini,
for example, can give a very different response than stretching it
between two internal residues.[35,36] The field of molecular biome-
chanics is focused on understanding the influence of mechanical
forces on biomolecular systems. We are interested in how mol-
ecules can sense and transmit force, and how mechanical forces
can modulate protein activity.We classify molecular biomechani-
cal studies into two general areas: native and artificial.
Native Molecular Mechanical Systems
Here we refer to molecular systems, typically protein-based,
where force transduction plays an important role in physiology.
Prominent examples include force-activated kinase enzymes
found in muscle,[37–39] or sound-sensitive tip-link proteins that
generate signals in the inner ear.[40–44]Another prominent example
is the complex and highly regulated process of blood coagula-
tion.[45–48] Fibrin hydrogels which are the basic structural scaffold
ity, absence of non-specific interactions, colloidal stability and
averseness to aggregation. Recent work demonstrated that bio-
physical stability is predictive of developability for a panel of
monoclonal antibodies.[3] Biophysical stability assays include
equilibrium-based methods such as affinity-capture self-interac-
tion nanoparticle spectroscopy (AC-SINS), clone self-interaction
by bio-layer interferometry (CSI-BLI), and thermal melting tem-
perature assessed by circular dichroism (CD) or nanoscale differ-
ential scanning fluorescence (nanoDSF). If a therapeutic scores
poorly on one of these equilibrium-based stability assays, it is
much more likely to fail in the pharmaceutical development pipe-
line. Biophysical stability assays are time-consuming, costly and
consume large amounts of sample, and this failure mechanism
wastes a significant amount of time and money during drug de-
velopment. If we could develop improved methods for efficiently
screening and characterizing biophysical stability of therapeutic
compounds, we could accelerate this pipeline and rapidly contrib-
ute to next-generation therapies.
One of the limitations of the current paradigm is that biophys-
ical screening is conducted at equilibrium. All the assays used
for this purpose expose an ensemble of molecules to a uniform
temperature and pressure, and determine the ratio of denatured
to folded sample, or otherwise provide ensemble averages of
the behavior of billions of molecules under equilibrium condi-
tions. Living cells, tissues and organs, however, are notoriously
non-equilibrium systems. Molecules can be acted upon through
mechanical forces or chemical reactions requiring energy input
to the molecules, and these factors are not well represented in
equilibrium screens. Protein aggregation, for example, can be ini-
















Fig. 1. Recently approved therapeutic compounds illustrating the tran-
sition from small molecule drugs to protein biopharmaceuticals. As
molecular mass increases, atomic structures are no longer defined and
structures sample an ensemble of conformations. This raises the impor-
tance of folding and biophysical stability as crucial in developing next-
generation therapeutics.
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of blood clots exhibit strain-stiffening which is crucial for their
role in preventing blood loss under contractile shear stress.[49,50]
Cell adhesion to the extracellular matrix is another mechanically
regulated native process where integrins concentrate at focal ad-
hesions and participate in complexmechanically-activated signal-
ing.[51] Mechanostable adhesion proteins is furthermore essential
in bacterial pathogenesis.[52] Bacteria are required to adhere to
human tissues under shear stress, and have evolved adhesin pro-
teins that exhibit force-activated binding[53] to meet this challenge.
Currently, the strongest known protein–protein interactions occur
between these adhesins and human extracellular matrix proteins
including fibrinogen and fibronectin.[54,55]
Artificial Molecular Mechanical Systems
Here we refer to systems where force is not a physiological pa-
rameter, but can be used to perturb an artificial system. Engineered
artificial binding proteins can be developed to influence mechani-
cal aspects of a target protein’s physiology. Experimenters have
used single-molecule mechanical manipulation to learn about
proteins that have non-mechanical functions, and build synthetic
mechanobiological systems. For example, single-molecule me-
chanical manipulation has been used to reveal the strength of met-
al coordination centers in proteins[56,57] that otherwise have nome-
chanical role in vivo. Also, the mechanical activation of disulfide
bond reduction reactions involving thiolated nucleophiles[58,59] or
reducing enzymes[60,61] can be studied with single-molecule ma-
nipulation methods. Single-molecule cut-and-paste[62] relying on
a hierarchy of DNA dissociation forces in shear- or zip orientation
has been used to assemble molecular patterns from the bottom-up.
These studies indicate how mechanical forces can be used as an
independent variable to accelerate chemical reactions that oth-
erwise would not be observable on a realistic experimental tim-
escale. This is closely related to the field of mechanochemistry,
but here we are focused primarily on proteins and not synthetic
polymeric materials.
As our understanding of molecular mechanics improves, we
will see a more significant role for mechanopharmacology, which
encompasses new therapeutic approaches that specifically target
mechanical aspects of molecular and cellular (patho)physiology.
In this direction, it is known for example that antibody thera-
peutics can dock and modulate the mechanical stability of the
CD4 receptor domain required for HIV entry into cells.[63] Also,
mechanical stability of immunoglobulin domains inversely cor-
relates with their rates of nuclear pore complex translocation[64]
when fused with transcription factors, with implications on drug
delivery or deliver of CRISPR-Cas therapeutics. For our part, our
group is pursuing the application of mechanical forces to bio-
pharmaceutical proteins as a method to characterize biophysical
stability that can inform developability assessments in biopharma.
Part 2 – Polymers and Hydrogels in Protein
Engineering
Stimuli-responsive Synthetic Polymers
Stimuli-responsive or ‘smart’ polymers are repetitive syn-
thetic polymers that respond to small changes in environmental
conditions by undergoing large changes in molecular conforma-
tion.[65] Often times these materials lose solubility above a critical
temperature, referred to as the lower critical solution temperature
(LCST). Some of the most widely used synthetic smart polymers
include poly(N-isopropylacrylamide) and poly(oligoethylene
glycol methacrylate). These polymers can be readily polymer-
ized from the surface of proteins by attaching ATRP initiators of
RAFT agents and allowing polymerization to proceed from the
protein surface in a ‘grafting-from’ synthetic approach, or alter-
natively site specifically conjugated to proteins near their active
sites already as full-length polymers.[66] Attachment near the ac-
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Fig. 2. Molecular biomechanics. (A) Single-molecule atomic force mi-
croscopy can be used to apply mechanical tension to individual protein
domains and receptor-ligand complexes, and study unfolding and
unbinding reactions under force. (B) Schematic of a typical data curve
showing stretching of a single polyproteins, unfolding of fingerprint
domains and rupture of receptor-ligand complexes. Non-linear entropic
spring models of polymer elasticity are used to map the force-extension
response into force-contour length space. This allows us to make
domain assignments in the unfolding traces and understand which
segments of the molecule are being mechanically denatured along the
unfolding/unbinding reaction pathway.
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enhanced by directed evolution include catalytic turnover rate,
substrate binding affinity, substrate specificity/selectivity, as well
as biophysical stability and can be conceived of as exploration of
a multidimensional sequence/fitness landscape.[75]
Directed evolution essentially runs in an iterative process. In
the first step, genetic diversity is generated by making mutations
to the parent gene that encodes the enzyme. Many strategies can
be used in designing and synthetizing gene libraries for directed
evolution, for example, libraries may be based on error-prone
PCR, homologous sequences, gene shuffling, and computational
or rational design, as well as many other approaches. Following
generation of genetic diversity, genes are transformed into an ex-
pression host such that each cell expresses only one variant from
the library. Next, each variant must be screened or the host cells
must be exposed to a selection pressure such that variants ex-
hibiting enhanced phenotypic fitness survive. If a selection pres-
sure cannot be developed that biochemically links enzyme activ-
ity with survival probability of the host, a screening approach is
instead used which tests variants individually and ranks them in
terms of phenotypic fitness under the screening condition. For
typical screens, microbial colonies expressing a single variant
would be inoculated into a 96-well plate and screened for en-
zymatic turnover using a colorimetric assay, or other suitable
method for product quantification. Following the screening stage,
the best performing variants can be combined and diversified, and
the entire process is repeated in iterative rounds to improve the
performance of the enzyme.
The screening stage is generally considered the bottleneck in
directed evolution. The throughput of such screening campaigns
is significantly limited by the requirement of achieving reaction
compartmentalization to establish a genotype-phenotype linkage.
The requirement of compartmentalizing individual clones using
parallel multi-well cell culture and enzymatic turnover assays is
laborious and slow. Typically, screening is done on cell lysates us-
ing robotic automation, which is complex, costly and achievable
at a maximal rate of ~104 clones/week.
To address these significant barriers in enzyme directed evo-
lution, we recently developed a hydrogel polymerization meth-
od[76,77] which provides yeast cells with an artificial phenotype
that can be correlated with enzyme fitness. The reaction chemistry
we developed allows yeasts to auto-encapsulate inside synthetic
hydrogel capsules (Fig. 3) in response to enhanced activity of the
target enzyme. The encapsulation reaction is dependent on the
activity level of the target enzyme displayed on the outer cell wall.
Exposure of cells to a reaction mixture containing macromono-
mer gel precursors along with the substrate of the enzyme initiates
a reaction cascade that results in enzyme-mediated polymeriza-
tion and cross-linking of a hydrogel capsule around individual
cells. This approach offers a new genotype-phenotype linkage
for directed evolution where one-pot reactions are completed in
minutes and can be used to screenmultimillion-member variant li-
braries under selective stress. We have several methods to perturb
the enzyme variant library in order to screen for different molecu-
lar behaviors including folding stability, thermostability, catalytic
turnover rate, or improved substrate binding affinity. This local-
ized enzyme-mediated polymerization chemistry allows us to
push the limits of laboratory directed evolution further, and com-
bine with next-generation DNA sequencing technologies[78,79] to
understand sequence fitness landscapes at unprecedented scale.
In summary, I have provided a general overview for a chemi-
cally literate audience on the active themes in my group which
concentrate on two areas: (1) molecular biomechanics of proteins
and (2) polymers and hydrogels in protein engineering and di-
rected evolution. These areas are connected in that they both seek
to understand the relationships between sequence, structure and
biophysical stability of therapeutics. The candidate molecules of
interest for our investigations are primarily biotherapeutics, with
tive site and phase separation can be used to modulate protein
function, such as switching enzyme activity in response to eternal
stimuli.[67,68]
However, synthetic polymer chemistry suffers from several
limitations for therapeutics development. The polydispersity in-
herent in organic polymer synthesis results in a distribution of
molecule lengths that could be problematic for clinical approval
of therapeutics or drug delivery vehicles. Structure–function re-
lationships are blurred when the sample is heterogeneous and
tolerances for the molecular weight distribution need to be well-
defined. To address this, protein-based polymers may be a valu-
able alternative.
Protein-based Polymers
Protein-based polymers are repetitive polymers comprising
repeating segments of amino acids. They are genetically-encoded
and produced in recombinant expression hosts, therefore com-
pletely monodisperse. Typically, protein-based polymers are ei-
ther intrinsically disordered or adopt a weak helical conformation
in aqueous solutions. A classical example is that of elastin-like
polypeptides (ELPs) which comprise repeating (VPGXG)
n
motifs
where X can take the identify of any amino acid except proline.
ELPs are artificial protein sequences derived from the na-
tive sequence of human tropoelastin, which is a highly flexible
extracellular protein containing alternating hydrophilic and hy-
drophobic domains. In humans, there are 13 isoforms all derived
from the ELN gene by alternative splicing. The molecular weight
of these individual isoforms ranges from approx. 50–70 kDa.
Tropoelastin functions as the soluble precursor molecule of elas-
tin, and after its expression in the cell it is secreted and forms
aggregates that are cross-linked and incorporated into growing
elastic fibers. With a half-life in the body of >70 years, elastin
is highly stable and a fundamental component of the extracel-
lular matrix (ECM) of tissues whose function requires flexibility
(e.g. blood vessels, heart, lung or skin). Elastin provides elasticity
and strength and enables these tissues to return to their original
shape after being stretched. Besides that, elastin is also involved
in wound healing.
OriginatingfrommyPhDworkat theUniversityofWashington,
Seattle,[69–71] my group continues to be active in developing new
molecular systems incorporating both ELPs and synthetic smart
polymers for applications in diagnostics, biomarker detections.
We have implemented ELPs in single-molecule mechanical ex-
periments to achieve uniform deformation and avoid mechano-
isomerization reactions that are observed with PEG.[24] In other
recent work, we combined magnetic nanoparticles modified with
poly(N-isopropylacrylamide) together with an alternative binding
scaffold (Cohesin) that was fused with an ELP. By raising the tem-
perature of the sample above the LCST of both the nanoparticles
and the ELP-fusion protein, we foundwewere able to magnetical-
ly entrain and separate biomarkers bound to the Cohesin scaffold.
This allowed us to perform biomarker separation and enrichment
and to detect the target with higher sensitivity.[72] In other work,
we incorporated non-canonical amino acids into ELPs and used
them as an assembly point for building multi-valent biosensing
surfaces. This was innovative because multi-site non-canonical
amino acid incorporation into ELPs had not yet been demon-
strated, and was useful for increasing the binding capacity of the
immunoassay surface.[73]
Hydrogels for High-throughput Screening of Enzymes
One large ongoing effort for us seeks to improve workflows
for directed evolution by bringing in concepts from the fields of
polymer and hydrogel engineering. Directed evolution is a labora-
tory method for improving phenotypic properties of proteins, and
has been used extensively to enhance therapeutics enzymes for
biopharmaceutical applications.[74] Enzyme properties that can be
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a focus on alternative affinity proteins and binding scaffolds as
well as therapeutic enzymes. In the future, advanced biophysical
characterization methods and new approaches to high-through-
put screening will allow us to generate vast datasets with paired
sequence-function information. These will set the stage for data-
driven protein engineering and advance our understanding of op-
timal design parameters for biotherapeutics.
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